Angiocidin - Protheragen
Latest Information Update: 11 Oct 2021
At a glance
- Originator Protheragen
- Class Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors; TNFRSF21 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute myeloid leukaemia
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 11 Oct 2021 Angiocidin - Protheragen is available for licensing as of 11 Oct 2021. https://www.protheragen.com/available-projects/a-novel-therapeutic-recombinant-protein-for-aml/
- 11 Oct 2021 Protheragen has patent protection for Angiocidin for treatment of Acute myeloid leukaemia in USA before October 2021 (Protheragen's pipeline, October 2021)
- 11 Oct 2021 Pharmacodynamics data from preclinical trial in Acute myeloid leukaemia released by Protheragen before October 2021 (Protheragen's pipeline, October 2021)